What does Savara Inc. do?
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary…
What is Savara Inc.'s P/E and P/B ratio?
Savara Inc. has a P/E ratio of -7.8 and a P/B ratio of 6.49.
What is Savara Inc.'s debt-to-equity ratio?
Savara Inc. has a debt-to-equity ratio of 0.21.
How much does Savara Inc. owe compared with what it owns?
Savara Inc. owes $0.25 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Savara Inc.'s Positivity rank?
Savara Inc. is ranked #5,439 of 6,774 companies globally and #2,957 of 4,000 in United States on PositoAI, with a Positivity Score of 17,396.
Does Savara Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Savara Inc..
Where can I read the latest news about Savara Inc.?
Recent headlines about Savara Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Savara Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Savara Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.